key: cord-0726074-qf3ebsm6
authors: Bianchi, Leonardo; Biondi, Filippo; Hansel, Katharina; Murgia, Nicola; Tramontana, Marta; Stingeni, Luca
title: Skin tests in urticaria/angioedema and flushing to Pfizer‐BioNTech SARS‐CoV‐2 vaccine: Limits of intradermal testing
date: 2021-04-22
journal: Allergy
DOI: 10.1111/all.14839
sha: c5bf4969612ba467ef2e3f14bb9462b5314028ec
doc_id: 726074
cord_uid: qf3ebsm6

nan

To the Editor, Table 1 .

These patients underwent an allergologic workup with Pfizer-BioNTech vaccine as suggested by EAACI 4 and German allergy centres. 5 In absence of standardized methodology for this vaccine testing, we referred to Italian 6 and EAACI recommendations. 7 Unusable vaccine residues, regain from the vaccine campaign, were 

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of the current authorized COVID-19 vaccines

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Practical recommendations for the allergological risk assessment of the COVID-19 vaccination -a harmonized statement of allergy centers in Germany

Skin tests in the diagnosis of adverse drug reactions

Skin test concentrations for systemically administered drugs -an ENDA/EAACI Drug Allergy Interest Group position paper